Physician profile
Edward S Lee
NPI 1629265657
$49,770.92
in general payments reported to CMS, 2019-2025
24 companies · $29K in 2025
The $29K reported for 2025 was more than what 98% of Plastic and Reconstructive Surgery providers received nationally (typical 2025 total: $445).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $294 · 2020: $18.55 · 2021: $6,115 · 2022: $1,082 · 2023: $4,025 · 2024: $9,669 · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $23K · Food and Beverage: $9,947 · Travel and Lodging: $5,973 · Honoraria: $2,000 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $849 · Entertainment: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $23,375.00 |
| Food and Beverage | $9,947.41 |
| Travel and Lodging | $5,972.66 |
| Honoraria | $2,000.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $849.00 |
| Entertainment | $117.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Musculoskeletal Transplant Foundation INC. | $30,589.71 | 2021-2025 | |
| Polynovo North America LLC | $4,077.85 | 2022-2025 | Novosorb Btm |
| Davol INC. | $3,494.43 | 2021-2024 | Phasix Mesh |
| Abbvie INC. | $3,164.79 | 2023-2025 | |
| Tela Bio, INC. | $2,105.61 | 2024-2025 | Ovitex 2s, Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Allergan, INC. | $2,029.58 | 2019-2022 | |
| Integra Lifesciences Corporation | $752.25 | 2020-2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Axogen | $699.92 | 2021-2025 | Axoguard Ha+ Nerve Protector |
| Depuy Synthes Sales INC. | $566.91 | 2021-2024 | Xcm Biologic Tissue Matrix, Trumatch |
| Smith+Nephew, INC. | $458.12 | 2019-2024 | Pico 14, Renasys Touch, Renasys Go V2 Home |
| Mentor Worldwide LLC | $360.66 | 2021-2025 | Mentor Memorygel Resterilizable Gel Sizer, Artoura Breast Tissue Expander, Mentor Cpx 2 Breast Tissue Expander |
| Innovation Technologies INC | $216.09 | 2024 | Irrisept |
| Avita Medical Americas, LLC | $211.26 | 2025 | Permeaderm, Recell, Cohealyx |
| Acera Surgical, INC. | $201.64 | 2023-2025 | Restrata Wound Matrix |
| Stryker Corporation | $172.26 | 2025 | Medpor, Vsp System, Vsp Cranial |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $145.01 | 2024 | Affixus |
| Ethicon US, LLC | $123.78 | 2025 | Evarrest, Stratafix, Vistaseal |
| Rti Surgical, INC | $110.53 | 2025 | |
| Janssen Pharmaceuticals, INC | $100.17 | 2021 | |
| C. R. Bard, INC. & Subsidiaries | $59.00 | 2022 | |
| Acumed LLC | $58.36 | 2023 | Acumed |
| Kci USA, INC. | $43.54 | 2021-2023 | V.A.C.Ulta, V.A.C.Instill, Prevena |
| Convatec INC. | $17.33 | 2019 | |
| Checkpoint Surgical, INC | $12.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.